Non-alcoholic fatty liver disease (NAFLD), and the more necro-inflammatory and progressive NASH, is an emerging disease, highly associated with features of the metabolic syndrome (obesity y, type 2 diabetes/insulin resistance, dyslipidemia). Indeed, many believe that it is a precursor for insulin resistance driven type 2 diabetes. Current estimates suggest that up to 75% or more obese people exhibit NAFLD and of those 20-30% will progress to NASH within approx. ten years. NASH can further progress to cirrhosis and liver failure.
In the near future NASH will become the primary reason for a liver transplant in the US. Currently, there are no approved therapeutics for the treatment of NASH, although several phase 2 and 3 trials are ongoing exploring the efficacy and outcomes of pro-metabolic (GLP-1 receptor agonists, FXR agonists, PPAR agonists), anti-fibrotic (ASK-1 inhibitor, galectin-3) and anti-inflammatory (pan-caspase inhibitor) pathways.
• To identify circulating proteins (or specific PTMs) that correlate with key features of liver histopathology, primarily fibrosis, inflammation and/or hepatocyte ballooning, in the context of NASH in rodent and/or hepatocellular or liver tissue ex vivo models.
• To explore the biological mechanism/s of action of key factor/s in the pathogenesis or resolution of NASH in in vitro and/or in vivo models.
• To validate these factor/s in human clinical cohorts to determine their predictive validity in identifying NASH patients and/or with NASH resolution in clinical trial cohorts or subsets of human subjects.
• To perform methodological developments within the clinical proteomics field and in PTMomics characterization of cellular signalling pathways.
The project is a joint project between the research group of Professor Martin R. Larsen, Department of Biochemistry and Molecular Biology at the University of Southern Denmark, the Danish Diabetes Academy and the company MedImmune.
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines.
A successful candidate would have a PhD degree in biochemistry, cell biology, molecular biology, proteomics or a related field and is highly motivated and innovative. A candidate with significant experience in functional proteomics, post-translational modification analysis, LC-based mass spectrometry and bioinformatics is preferable. However, knowledge in diabetes and NASH diseases is a significant merit. Excellent communication and writing skills and an ability to interact socially and scientifically with other laboratory members and collaborators are essential. Previous postdoc experience and a strong publication record are also strong merits.
For further information please contact
Professor Martin R. Larsen, PhD, SDU, e-mail: firstname.lastname@example.org
Application, salary etc.
The successful applicant will be employed in accordance with the agreement between the Ministry of Finance and AC (the Danish Confederation of Professional Associations). Please check links for more information on salary and taxation.
The following documents must be submitted with your electronic application, and written in English:
• CV including date of public thesis defense and previous positions
• Complete list of publications
• Statement of research interests and previous achievements (max. one page)
• Signed letters of reference from at least two senior researchers (scanned copies acceptable). Should your referees wish to send their letters directly to us, please have them use e-mail: email@example.com mentioning your name and the title of the position in the subject line. And please note that these also need to reach us before deadline.
The position is limited to a duration of three years.
Shortlisting may be used in the assessment process.
Incomplete applications and applications received after the deadline will neither be considered nor evaluated.
To qualify you must have passed a PhD or equivalent. Applications will be assessed by an expert assessor/committee. Applicants will be informed of their assessment by the university.
The University wishes our staff to reflect the diversity of society and thus welcomes applications from all qualified candidates regardless of personal background.
Applications must be submitted electronically using the link "Apply online". Attached files must be in Adobe PDF or Word format. Each box can only contain a single file of max. 10 Mb. We strongly recommend that you read How to apply before you apply.
Further information for international applicants about entering and working in Denmark.